TY - JOUR
T1 - Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents
AU - Marzola, Pasquina
AU - Ramponi, Simona
AU - Nicolato, Elena
AU - Lovati, Emanuela
AU - Sandri, Marco
AU - Calderan, Laura
AU - Crescimanno, Caterina
AU - Merigo, Flavia
AU - Sbarbati, Andrea
AU - Grotti, Adriana
AU - Vultaggio, Stefania
AU - Cavagna, Friederich
AU - Lorusso, Vito
AU - Osculati, Francesco
PY - 2005/7
Y1 - 2005/7
N2 - Objectives: The aim of this study was to compare the efficacy of gadoteridol, B22956/1 (a new protein binding blood pool contrast agent), and (Gd-DTPA)37-albumin in detecting, by dynamic contrast-enhanced magnetic resonance imaging (MRI), the effect in vivo of tamoxifen in an experimental model of breast tumor implanted in rats. Materials and Methods: Tumors were induced by subcutaneous injection of 106 mammary adenocarcinoma cells (13762 MAT B III). Treatment with tamoxifen (or vehicle) started on day 4 after implantation. On day 10 after implantation, animals were observed by MRI using B22956/1 (or gadoteridol) and, 24 hours later, using (Gd-DTPA)37-albumin. Results: Dynamic contrast-enhanced magnetic resonance imaging data showed that tamoxifen treatment decreased vascular permeability to B22956/1, whereas no difference was detectable in permeability to gadoteridol or to (Gd-DTP A)37-albumin. No effect on fractional plasma volume was detected with either of contrast agents. Conclusions: B22956/1 is superior to both small Gd chelates and macromolecular contrast agents in the assessment of the effect of tamoxifen treatment on tumor vasculature.
AB - Objectives: The aim of this study was to compare the efficacy of gadoteridol, B22956/1 (a new protein binding blood pool contrast agent), and (Gd-DTPA)37-albumin in detecting, by dynamic contrast-enhanced magnetic resonance imaging (MRI), the effect in vivo of tamoxifen in an experimental model of breast tumor implanted in rats. Materials and Methods: Tumors were induced by subcutaneous injection of 106 mammary adenocarcinoma cells (13762 MAT B III). Treatment with tamoxifen (or vehicle) started on day 4 after implantation. On day 10 after implantation, animals were observed by MRI using B22956/1 (or gadoteridol) and, 24 hours later, using (Gd-DTPA)37-albumin. Results: Dynamic contrast-enhanced magnetic resonance imaging data showed that tamoxifen treatment decreased vascular permeability to B22956/1, whereas no difference was detectable in permeability to gadoteridol or to (Gd-DTP A)37-albumin. No effect on fractional plasma volume was detected with either of contrast agents. Conclusions: B22956/1 is superior to both small Gd chelates and macromolecular contrast agents in the assessment of the effect of tamoxifen treatment on tumor vasculature.
KW - Angiogenesis
KW - Contrast agents
KW - DCE-MRI
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=20844439728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20844439728&partnerID=8YFLogxK
U2 - 10.1097/01.rli.0000167124.89782.db
DO - 10.1097/01.rli.0000167124.89782.db
M3 - Article
C2 - 15973133
AN - SCOPUS:20844439728
VL - 40
SP - 421
EP - 429
JO - Investigative Radiology
JF - Investigative Radiology
SN - 0020-9996
IS - 7
ER -